Capricorn Fund Managers’s Avita Medical RCEL Stock Holding History

Capricorn Fund Managers’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-22,287	Closed	-$267K	–	110
2021 Q4	$267K	Buy	+22,287	New	+$340K	0.08%	72

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Capricorn Fund Managers's RCEL Position: Q1 2022 in Review

Capricorn Fund Managers sold out of Avita Medical (RCEL) in Q1 2022, closing a stake of 22,287 shares — an estimated $267K sold.

Capricorn Fund Managers first reported a position in RCEL in Q4 2021 and held it in 1 quarter. The position peaked at $267K in Q4 2021. 69 funds tracked by Wall St. Rank hold RCEL as of Q1 2022.

Capricorn Fund Managers reported no remaining Avita Medical position as of Q1 2022 after selling out during the quarter.
Capricorn Fund Managers sold 22,287 Avita Medical shares in Q1 2022, an estimated $267K.
Capricorn Fund Managers first reported a position in Avita Medical in Q4 2021 and held it in 1 quarter.
Capricorn Fund Managers's Avita Medical position peaked at $267K in Q4 2021.
69 funds tracked by Wall St. Rank held Avita Medical as of Q1 2022.

Based on Capricorn Fund Managers's 13F filing for Q1 2022, filed 10 May 2022.